Hyloris Pharmaceuticals (LTS:0AB6) EBIT per Share : €-0.55 (TTM As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Hyloris Pharmaceuticals EBIT per Share?

Hyloris Pharmaceuticals's EBIT per Share for the six months ended in Dec. 2023 was €-0.32. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.55.

During the past 3 years, the average EBIT per Share Growth Rate was -31.10% per year. During the past 5 years, the average EBIT per Share Growth Rate was -20.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Hyloris Pharmaceuticals's EBIT per Share or its related term are showing as below:

LTS:0AB6' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -31.1 Med: -19.95 Max: -15.9
Current: -31.1

During the past 8 years, the highest 3-Year average EBIT per Share Growth Rate of Hyloris Pharmaceuticals was -15.90% per year. The lowest was -31.10% per year. And the median was -19.95% per year.

LTS:0AB6's 3-Year EBIT Growth Rate is ranked worse than
82.68% of 1305 companies
in the Biotechnology industry
Industry Median: 3.5 vs LTS:0AB6: -31.10

Hyloris Pharmaceuticals's EBIT for the six months ended in Dec. 2023 was €-8.84 Mil.

Hyloris Pharmaceuticals EBIT per Share Historical Data

The historical data trend for Hyloris Pharmaceuticals's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hyloris Pharmaceuticals EBIT per Share Chart

Hyloris Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-0.23

-0.28

-0.42

-0.39

-0.55

Hyloris Pharmaceuticals Semi-Annual Data
	Dec17	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBIT per Share	Get a 7-Day Free Trial							-0.11	-0.15	-0.22	-0.23	-0.32

Hyloris Pharmaceuticals EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Hyloris Pharmaceuticals's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-15.369	/	28.0004
=	-0.55

Hyloris Pharmaceuticals's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-8.835	/	28.0004
=	-0.32

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.55

Hyloris Pharmaceuticals (LTS:0AB6) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Hyloris Pharmaceuticals EBIT per Share Related Terms

Thank you for viewing the detailed overview of Hyloris Pharmaceuticals's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Hyloris Pharmaceuticals (LTS:0AB6) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hyloris Pharmaceuticals SA (LTS:0AB6) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

52U:Germany HYL:Belgium

Address

Boulevard Patience et Beaujonc N°3/1, Liege, BEL, 4000

Website

https://www.hyloris.com

Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans these areas such as Cardiovascular, Other Reformulations, and Established markets (high-barrier generics). It has two early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic IV, a non-opioid analgesic product for the treatment of pain.

Hyloris Pharmaceuticals (LTS:0AB6) Headlines

No Headlines